Health Technology · Pharmaceuticals: Major · NSE: REMUS · data 2026-10-09
Remus Pharmaceuticals Ltd.
Health check: Strong (8.5/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹976.35
Market cap
₹1,153 cr
P/E
31.1
P/B
3.3
ROE
12.2%
ROCE
14.7%
Debt / equity
0.08
Dividend yield
0.10%
1-year return
42.5%
52-week high
₹1,009.95
52-week low
₹580
Operating margin
6.3%
Growth
| Revenue (last 12 months) | ₹854 cr |
| Net profit (last 12 months) | ₹37 cr |
| Sales growth, 3 years (yearly) | 166.6% |
| Profit growth, 3 years (yearly) | 63.2% |
Similar companies
Bharat Parenterals Ltd. (BPLPHARMA) · Kopran Limited (KOPRAN) · Lincoln Pharmaceuticals Ltd (LINCOLN) · Sigachi Industries Limited (SIGACHI) · Bajaj Healthcare Ltd (BAJAJHCARE)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open REMUS in NSE Scanner →